NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: Novel therapeutic implications

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Clementz, Anthony G ^a   Rogowski, Allison ^a   Pandya, Kinnari ^a   Miele, Lucio ^b   Osipo, Clodia ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; GAMMA SECRETASE INHIBITOR; LIPOCORTIN 5; LUCIFERASE; MRK 003; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PROTEIN C JUN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR PEA3; UNCLASSIFIED DRUG; NOTCH RECEPTOR; NOTCH1 PROTEIN, HUMAN; NOTCH2 PROTEIN, HUMAN; NOTCH3 PROTEIN, HUMAN; NOTCH4 PROTEIN, HUMAN; ONCOPROTEIN; PEPTIDE FRAGMENT; SECRETASE; STRESS ACTIVATED PROTEIN KINASE; TAM67 PEPTIDE; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NOTCH 1 ONCOGENE; NOTCH 2 GENE; NOTCH 3 GENE; NOTCH 4 ONCOGENE; ONCOGENE; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

AMYLOID PRECURSOR PROTEIN SECRETASES; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; RECEPTORS, NOTCH; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84860390108     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2900     Document Type: Article

References (75)

1. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398. 10.1073/pnas.1732912100, 193572, 12917485.
2. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800. 10.1056/NEJMra0801289, 19228622.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
4. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
5. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280.
6. Miele L. Rational targeting of Notch signaling in breast cancer. Expert Rev Anticancer Ther 2008, 8:1197-1202. 10.1586/14737140.8.8.1197, 18699758.
7. Blaumueller CM, Artavanis-Tsakonas S. Comparative aspects of Notch signaling in lower and higher eukaryotes. Perspect Dev Neurobiol 1997, 4:325-343.
8. Dunwoodie SL, Henrique D, Harrison SM, Beddington RS. Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development 1997, 124:3065-3076.
9. Lindsell CE, Shawber CJ, Boulter J, Weinmaster G. Jagged: a mammalian ligand that activates Notch1. Cell 1995, 80:909-917. 10.1016/0092-8674(95)90294-5, 7697721.
10. Shawber C, Boulter J, Lindsell CE, Weinmaster G. Jagged2: a serrate-like gene expressed during rat embryogenesis. Dev Biol 1996, 180:370-376. 10.1006/dbio.1996.0310, 8948600.
11. Callahan R, Raafat A. Notch signaling in mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia 2001, 6:23-36. 10.1023/A:1009512414430, 11467450.
12. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israël A. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000, 5:207-216. 10.1016/S1097-2765(00)80417-7, 10882063.
13. Saxena MT, Schroeter EH, Mumm JS, Kopan R. Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis. J Biol Chem 2001, 276:40268-40273.
14. Hsieh JJ, Zhou S, Chen L, Young DB, Hayward SD. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci USA 1999, 96:23-28. 10.1073/pnas.96.1.23, 15086, 9874765.
15. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet 2000, 26:484-489. 10.1038/82644, 11101851.
16. Maier MM, Gessler M. Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun 2000, 275:652-660. 10.1006/bbrc.2000.3354, 10964718.
17. Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notchic: implication for cell cycle disruption in transformation by Notchic. Mol Cell Biol 2001, 21:5925-5934. 10.1128/MCB.21.17.5925-5934.2001, 87311, 11486031.
18. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, del Bianco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolfe MS, Shachaf C, Felsher D, Blacklow SC, Pear WS, Aster JC. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006, 20:2096-2109. 10.1101/gad.1450406, 1536060, 16847353.
19. Efferson CL, Winkelmann CT, Ware C, Sullivan T, Giampaoli S, Tammam J, Patel S, Mesiti G, Reilly JF, Gibson RE, Buser C, Yeatman T, Coppola D, Winter C, Clark EA, Draetta GF, Strack PR, Majumder PK. Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 2010, 70:2476-2484. 10.1158/0008-5472.CAN-09-3114, 20197467.
20. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S, Tagliabue E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 2009, 15:2010-2021. 10.1158/1078-0432.CCR-08-1327, 19276287.
21. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene 2008, 27:5019-5032. 10.1038/onc.2008.149, 18469855.
22. Watters JW, Cheng C, Majumder PK, Wang R, Yalavarthi S, Meeske C, Kong L, Sun W, Lin J, Heyer J, Ware C, Winter C, Reilly JF, Demuth T, Clark S, Chiu MI, Robinson MO, Kohl N, Kannan K. De novo discovery of a γ-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res 2009, 69:8949-8957. 10.1158/0008-5472.CAN-09-1544, 19903844.
23. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008, 68:5226-5235. 10.1158/0008-5472.CAN-07-5744, 18593923.
24. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE, Reedijk M. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 2007, 20:685-693. 10.1038/modpathol.3800785, 17507991.
25. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005, 65:8530-8537. 10.1158/0008-5472.CAN-05-1069, 16166334.
26. Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, O'Malley FP, Egan SE, Andrulis IL. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 2008, 111:439-448. 10.1007/s10549-007-9805-3, 17990101.
27. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010, 70:709-718. 10.1158/0008-5472.CAN-09-1681, 20068161.
28. Hu C, Diévart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 2006, 168:973-990. 10.2353/ajpath.2006.050416, 1606519, 16507912.
29. Yamaguchi N, Oyama T, Ito E, Satoh H, Azuma S, Hayashi M, Shimizu K, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Ohwada S, Tatsuta K, Inoue J, Semba K, Watanabe S. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 2008, 68:1881-1888. 10.1158/0008-5472.CAN-07-1597, 18339869.
30. O'Neill CF, Urs S, Cinelli C, Lincoln A, Nadeau RJ, León R, Toher J, Mouta-Bellum C, Friesel RE, Liaw L. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol 2007, 171:1023-1036. 10.2353/ajpath.2007.061029, 1959488, 17675579.
31. Alimirah F, Panchanathan R, Davis FJ, Chen J, Choubey D. Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. Neoplasia 2007, 9:427-434. 10.1593/neo.07211, 1877974, 17534448.
32. Wu J, Iwata F, Grass JA, Osborne CS, Elnitski L, Fraser P, Ohneda O, Yamamoto M, Bresnick EH. Molecular determinants of NOTCH4 transcription in vascular endothelium. Mol Cell Biol 2005, 25:1458-1474. 10.1128/MCB.25.4.1458-1474.2005, 548019, 15684396.
33. Trimble MS, Xin JH, Guy CT, Muller WJ, Hassell JA. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. Oncogene 1993, 8:3037-3042.
34. Iguchi A, Kitajima I, Yamakuchi M, Ueno S, Aikou T, Kubo T, Matsushima K, Mukaida N, Maruyama I. PEA3 and AP-1 are required for constitutive IL-8 gene expression in hepatoma cells. Biochem Biophys Res Commun 2000, 279:166-171. 10.1006/bbrc.2000.3925, 11112434.
35. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002, 277:18649-18657. 10.1074/jbc.M111415200, 11901151.
36. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about?. Matrix Biol 1997, 15:519-526. 10.1016/S0945-053X(97)90026-3, 9138284.
37. Hida K, Shindoh M, Yasuda M, Hanzawa M, Funaoka K, Kohgo T, Amemiya A, Totsuka Y, Yoshida K, Fujinaga K. Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities. Am J Pathol 1997, 150:2125-2132. 1858336, 9176403.
38. Tower GB, Coon CI, Belguise K, Chalbos D, Brinckerhoff CE. Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter. Eur J Biochem 2003, 270:4216-4225. 10.1046/j.1432-1033.2003.03821.x, 14519134.
39. Kapila S, Xie Y, Wang W. Induction of MMP-1 (collagenase-1) by relaxin in fibrocartilaginous cells requires both the AP-1 and PEA-3 promoter sites. Orthod Craniofac Res 2009, 12:178-186. 10.1111/j.1601-6343.2009.01451.x, 2753518, 19627519.
40. Shepherd TG, Kockeritz L, Szrajber MR, Muller WJ, Hassell JA. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol 2001, 11:1739-1748. 10.1016/S0960-9822(01)00536-X, 11719215.
41. Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv Cancer Res 1998, 75:1-55.
42. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001, 2:827-837.
43. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003, 303:11-34.
44. Bojović BB, Hassell JA. The transactivation function of the Pea3 subfamily Ets transcription factors is regulated by sumoylation. DNA Cell Biol 2008, 27:289-305. 10.1089/dna.2007.0680, 18447755.
45. Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kobayashi M, Totsuka Y, Kohgo T, Shindoh M. E1AF degradation by a ubiquitin-proteasome pathway. Biochem Biophys Res Commun 2005, 327:575-580. 10.1016/j.bbrc.2004.12.045, 15629152.
46. Wasylyk B, Hagman J, Gutierrez-Hartmann A. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 1998, 23:213-216. 10.1016/S0968-0004(98)01211-0, 9644975.
47. Evans CP, Stapp EC, Dall'Era MA, Juarez J, Yang JC. Regulation of u-PA gene expression in human prostate cancer. Int J Cancer 2001, 94:390-395. 10.1002/ijc.1469, 11745419.
48. Matsui K, Sugimori K, Motomura H, Ejiri N, Tsukada K, Kitajima I. PEA3 cooperates with c-Jun in regulation of HER2/neu transcription. Oncol Rep 2006, 16:153-158.
49. Curran T, Franza BR. Fos and Jun: the AP-1 connection. Cell 1988, 55:395-397. 10.1016/0092-8674(88)90024-4, 3141060.
50. Hesselbrock DR, Kurpios N, Hassell JA, Watson MA, Fleming TP. PEA3, AP-1, and a unique repetitive sequence all are involved in transcriptional regulation of the breast cancer-associated gene, mammaglobin. Breast Cancer Res Treat 2005, 89:289-296. 10.1007/s10549-004-2622-z, 15754128.
51. Matthews CP, Colburn NH, Young MR. AP-1 a target for cancer prevention. Curr Cancer Drug Targets 2007, 7:317-324. 10.2174/156800907780809723, 17979626.
52. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991, 1072:129-157.
53. Bièche I, Tozlu S, Girault I, Onody P, Driouch K, Vidaud M, Lidereau R. Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis 2004, 25:405-411.
54. Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, Kristensen GB, Reich R, Kopolovic J. The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis 2004, 21:191-199.
55. Discenza MT, Vaz D, Hassell JA, Pelletier J. Activation of the WT1 tumor suppressor gene promoter by Pea3. FEBS Lett 2004, 560:183-191. 10.1016/S0014-5793(04)00104-8, 14988020.
56. Firlej V, Ladam F, Brysbaert G, Dumont P, Fuks F, de Launoit Y, Benecke A, Chotteau-Lelievre A. Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription. J Cell Sci 2008, 121:3393-3402. 10.1242/jcs.027201, 18827017.
57. Kinoshita J, Kitamura K, Tanaka S, Sugimachi K, Ishida M, Saeki H. Clinical significance of PEA3 in human breast cancer. Surgery 2002, 13 1 Suppl:S222-S225.
58. Xia WY, Lien HC, Wang SC, Pan Y, Sahin A, Kuo YH, Chang KJ, Zhou X, Wang H, Yu Z, Hortobagyi G, Shi DR, Hung MC. Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat 2006, 98:295-301. 10.1007/s10549-006-9162-7, 16752078.
59. Notch-1 (Homo Sapiens). , http://www.ncbi.nlm.nih.gov/gene/4851
60. Notch-4 (Homo Sapien). , http://www.ncbi.nlm.nih.gov/gene/4855
61. Baert JL, Monté D, Musgrove EA, Albagli O, Sutherland RL, de LY. Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int J Cancer 1997, 70:590-597. 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H, 9052761.
62. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002, 21:7680-7689. 10.1038/sj.onc.1205883, 12400010.
63. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med 2006, 6:905-918. 10.2174/156652406779010830, 17168741.
64. Hida K, Shindoh M, Yoshida K, Kudoh A, Furaoka K, Kohgo T, Fujinaga K, Totsuka Y. Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma. Oral Oncol 1997, 33:426-430. 10.1016/S0964-1955(97)00047-X, 9509127.
65. Kaya M, Yoshida K, Higashino F, Mitaka T, Ishii S, Fujinaga K. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 1996, 12:221-227.
66. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A, Hassell JA. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997, 15:1513-1525. 10.1038/sj.onc.1201331, 9380403.
67. Chotteau-Lelievre A, Montesano R, Soriano J, Soulie P, Desbiens X, de LY. PEA3 transcription factors are expressed in tissues undergoing branching morphogenesis and promote formation of duct-like structures by mammary epithelial cells in vitro. Dev Biol 2003, 259:241-257. 10.1016/S0012-1606(03)00182-9, 12871699.
68. Shepherd T, Hassell JA. Role of Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 2001, 6:129-140. 10.1023/A:1009576801226, 11467448.
69. Nakamura T, Tsuchiya K, Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol 2007, 42:705-710. 10.1007/s00535-007-2087-z, 17876539.
70. Okamoto R, Tsuchiya K, Watanabe M. [Regulation of epithelial cell differentiation and regeneration in IBD] [in Japanese]. Nippon Shokakibyo Gakkai Zasshi 2007, 104:1165-1171.
71. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233. 10.1016/j.cell.2009.03.045, 2827930, 19379690.
72. Myers E, Hill AD, Kelly G, McDermott EW, O'Higgins NJ, Young LS. A positive role for PEA3 in HER2-mediated breast tumour progression. Br J Cancer 2006, 95:1404-1409. 10.1038/sj.bjc.6603427, 2360603, 17060941.
73. Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 2004, 10:7335-7346. 10.1158/1078-0432.CCR-04-0183, 15534110.
74. Song KS, Kim K, Chung KC, Seol JH, Yoon JH. Interaction of SOCS3 with NonO attenuates IL-1β-dependent MUC8 gene expression. Biochem Biophys Res Commun 2008, 377:946-951. 10.1016/j.bbrc.2008.10.084, 18952062.
75. Moellering RE, Cornejo M, Davis TN, Del BC, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE. Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462:182-188. 10.1038/nature08543, 2951323, 19907488.